

Medtronic

Medtronic Australasia Pty Ltd
ABN 47 001 162 661
Level 8, 11 Khartoum Road
Macquarie Park NSW 2113
Australia
www.medtronic.com.au
Tel: 61 2 9857 9000

Medtronic Australasia Pty Ltd FY25 Modern Slavery Statement

Medtronic Australasia strives to conduct its activities in a manner that reflects the global Medtronic Mission and [Code of Conduct](#) – which includes being a good corporate citizen, dealing fairly in business, behaving ethically, upholding human rights, supporting a safe and healthy workplace, doing business in an environmentally responsible manner, and complying with applicable law. We're committed to ensuring that our suppliers reflect our values and beliefs by conducting business in ways that are consistent with Medtronic's applicable policies and practices.

Reporting entity

In accordance with the *Modern Slavery Act 2018* (Cth), **Medtronic Australasia Pty Ltd** ACN 001 162 661, incorporated in Australia with a registered office of Level 8, 11 Khartoum Road, Macquarie Park, New South Wales, 2113 provides the following Modern Slavery Statement for the financial year starting 27 April 2024 and ending 25 April 2025 to be made available to the Federal Government Public Modern Slavery Register. The Modern Slavery Statement has been approved by the Medtronic Australasia Board of Directors on 22 October 2025.

The entities which Medtronic Australasia owns and controls include:

- Covidien Pty Ltd (ACN 003 143 502); and
- Medtronic New Zealand Limited (NZBN 9429000102308).

We have consulted with these entities in the preparation of this statement. Covidien Pty Ltd is dormant and is not purchasing or selling any products or services and has no supply chain.

Our operations

Medtronic PLC, headquartered in Dublin, Ireland, is the leading global healthcare technology company. Medtronic was founded in 1949 and today serves healthcare systems, physicians, clinicians, and patients in more than 150 countries worldwide. The company has over 95,000 employees around the world and more than 150 facilities. The company develops technologies and manufactures devices to treat various health conditions, such as cardiac devices, cranial and spinal robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Medtronic sells medical devices and therapies through a combination of direct sales representatives and independent distributors globally.

Medtronic's main operational offices are located in Minneapolis, MN, United States, and the administrative headquarters are located in Dublin, Ireland. Medtronic has a global presence, with regional locations across the world.

Medtronic Australasia Pty Ltd was established in 1973. It is an Australian Private Company and is ultimately owned by Medtronic PLC. Its headquarters are in Macquarie Park, Sydney, Australia, with hubs in Melbourne, Brisbane, Adelaide, Perth, and Auckland.

The term “**Medtronic Australasia**” in this statement refers to Medtronic Australasia Pty Ltd, while “**Medtronic**” refers to Medtronic PLC (listed on the New York Stock Exchange) and its subsidiaries. In this statement, the collective expressions ‘we’,

‘us’, ‘our’ may be used when we refer to Medtronic PLC and any entities which it owns or over which it has control, as we operate using group-wide policies and procedures to assess and manage risks of modern slavery.

Medtronic Australasia is a distributor of medical devices and services in the Australian market. Our main brand names are ‘Medtronic’, ‘MiniMed’ and ‘Covidien’.

Medtronic Australasia sells, loans, consigns, and services medical equipment to healthcare organisations, including provision of equipment for trials by healthcare professionals. Medtronic Australasia has a number of agents and distributors located in Australia and New Zealand who represent medical products on behalf of Medtronic Australasia. Agreements with agents and distributors include a requirement for compliance with the Global Distributor Code of Conduct, which includes a way for employees of those organisations to report a concern.

Medtronic Australasia does not have any manufacturing operations in Australia.

Modern slavery risks in our operations and supply chain

Medtronic’s Global Human Rights Framework and approach has been established to identify and prioritise the most significant human rights risks across our business operations. The approach integrates human rights due diligence and risk assessments processes across internal facilities and our supply chain and is guided by the United Nations Guiding Principles (UNGPs).

Medtronic’s global supply footprint, and complex supply chain, involves exposure to potential human rights risks across the global medical device supply environment. Medtronic is aware that industry specific sustainability risks have been identified in lower tiers of the medical device supply chain, due to the number of suppliers and the origin of production, use of sub-suppliers, and the nature of operations.

However, Medtronic’s overall conclusion from our human rights due diligence efforts for this reporting period, is that no adverse human rights impacts requiring further actions or remediation efforts were identified at the time of writing this report. Despite this, there are still potential risks of adverse impacts on human rights and decent working conditions in the supply chain that require ongoing efforts. As such, Medtronic globally continuously works to reduce potential risks of negative impacts by strengthening our due diligence processes and operating mechanism to ensure human rights risk are effectively identified and mitigated.

In addition, Medtronic Australasia has used the [Walk Free Foundation’s Global Slavery Index 2023](#) and other measures outlined *below* to understand and rate the risks of modern slavery practices in our local operations and supply chain.

Employees and shared service centres

(a) Overview

Medtronic Australasia employs more than 800 staff. The Medtronic employment relationship with all workers employed on a full time, part time, casual or fixed term arrangement are covered by common law contracts of employment. These contracts are underpinned by the *Fair Work Act 2009* (Cth) (“**Fair Work Act**”), which is federal legislation that ratifies the minimum terms and conditions of employment in Australia.

An employee engaged on a casual basis is provided with the opportunity to take full time work with Medtronic Australasia at 12 months of employment if they wish to do so and Medtronic Australasia is committed to this process. Employees engaged on a fixed term contract, otherwise known as Maximum Term Contracts, also enjoy terms and conditions of employment in accordance with the Fair Work Act.

Medtronic Australasia pays all employees, however engaged, a rate of pay significantly higher than the minimum rate of pay in Australia. The full employment package for all Medtronic employees includes a generous incentive payment scheme and access to the Medtronic Employee Share Plan as well as a Health and Wellbeing Allowance.

Our operations are also supported by shared service centres located in the Asia Pacific region:

- the AskHR enquiry centre in Singapore which is supported by regional Human Resources (“**HR**”) and Employee Relations (“**ER**”) partners. There is an ER support in The Philippines which is also supported by a regional HR partner;
- a Finance shared service centre in China;
- support for Quality and Regulatory Affairs, Customer Care, Supply Chain, and our Diabetes Operating Unit in The Philippines.

(b) Risk assessment

We consider that we have low inherent risks of modern slavery in our direct employee workforce based in Australia due to Medtronic Australasia’s local and global policies and expectations, and the corporate governance and industrial relations laws and frameworks that exist.

We also recognise that we have higher inherent risks in our indirect workforce because our shared service centres are in Asia Pacific, and this region has publicised issues with forced labour exploitation and higher average vulnerability scores in the Global Slavery Index. However, we consider our residual risk to be low because of the controls we have in place throughout Medtronic globally and because we have not received any reports about suspected modern slavery in this area to date.

Direct procurement

(a) Overview

Medtronic Australasia’s direct supply chain facilitates the delivery of Medtronic products from our manufacturing sites or third-party manufacturers to end users, either directly to hospitals or through intermediaries like agents, distributors, wholesalers and retail pharmacies. Although Medtronic Australasia does not manufacture products in Australia, the manufacturing and healthcare industries generally have higher inherent risks of modern slavery practices.

Globally, Medtronic sources materials and services from 61,000 partners across 120 countries, as detailed in the [Medtronic Impact Report](#). The products marketed and distributed by Medtronic Australasia in Australia are sourced from over 80 of Medtronic PLC’s manufacturing sites worldwide, primarily in the USA and European Union, with additional regional suppliers to Medtronic Australasia located in Australia, Switzerland, Germany, Ireland, China, and Japan.

According to the Walk Free, Global Slavery Index 2023, countries such as Mexico, Italy, Korea, and Japan have higher geographical risks of modern slavery compared to the USA and most EU members.

(b) Risk assessment

The Walk Free Foundation’s Global Slavery Index 2023 measures the scale and nature of modern slavery across 160 countries by combining data from over 40,000 survivor interviews, national household surveys in 75 countries, and statistical modelling of country-level risk factors such as conflict, governance, inequality, and access to basic needs. It ranks nations by prevalence and government response, using 141 indicators to assess laws, survivor support, and criminal justice efforts. By linking modern slavery to intersecting crises like poverty, migration, climate change, and conflict, the Index provides a data-driven foundation for governments, businesses, and civil society to strengthen transparency, accountability, and coordinated action to end modern slavery.

Given the countries we source our items that we sell into the Australia and the method we use to classify nations by their government response to modern slavery, our organisation’s exposure to slavery risk remains comparatively low. The vast majority of materials entering the Australian market originate from countries grouped under High Response or Very High Response categories¹ — those with strong legislative frameworks, enforcement capacity, and transparent supply-chain oversight as defined in the *Global Slavery Index 2023*.

By mapping our material sources against these government response tiers, we can demonstrate that only a small proportion of inputs are associated with countries rated Moderate Response, thereby reducing the likelihood that our manufacturing and

¹ Refer to Figure 3 on page 5 of this Statement for a breakdown of the Moderate Response, High Response and Very High Response groupings based on the *Global Slavery Index 2023* ratings.

sourcing activities indirectly support forced labour or exploitative practices. This structured, data-driven approach provides assurance that our sourcing strategy aligns with global best practice and supports continuous improvement in ethical supply-chain management.

Figure 1: Medtronic Australasia’s product range, grouped by source country’s Global Slavery Index 2023 rating by Government Response.





Figure 2: Medtronic Australasia’s product range grouped by source country’s Global Slavery Index 2023 rating by Government Response.



| Figure 3: Groupings of source country’s Global Slavery Index 2023 ratings by Government Response | | | |
|--|---------------|---------------|---------------|
| Group | Minimum Score | Maximum Score | Approx. Range |
| Very Low Response | -3 | 8 | -3 – 8 |
| Low Response | 10 | 29 | 10 – 29 |
| Moderate Response | 31 | 59 | 31 – 59 |
| High Response | 60 | 63 | 60 – 63 |
| Very High Response | 67 | 68 | 67 – 68 |

Indirect procurement

(a) Overview

Indirect procurement refers to all the goods and services that are not intended for sale to customers, but which are required by Medtronic Australasia's internal stakeholders to support its effective operations.

Medtronic Australasia's indirect procurement activities include but are not limited to:

- property fit out (construction);
- facility maintenance and cleaning services;
- telecommunication and IT services and products;
- professional services;
- marketing and media services;
- warehouse and freight services;
- equipment calibrations and maintenance;
- travel and accommodation;
- labour hire;
- insurances; and
- stationery.

(b) Risk assessment

Most of Medtronic Australasia's indirect procurement activities occur within Australia and New Zealand. Australia and New Zealand are deemed low-risk jurisdictions with a Global Slavery Index Prevalence Rate of 1.6 per 1,000 people.

However, as outlined above, Medtronic Australasia does procure goods and services from the construction and cleaning industries to support our commercial leases and facilities services. These industries are considered at risk of forced labour exploitation in Australia. Based on our assessment to date, we believe that the risks are low given Australia's corporate governance and industrial relations frameworks.

We also acknowledge that the supply chains of our indirect procurement suppliers may include sources from higher-risk jurisdictions, including throughout Asia Pacific.

Actions taken to address modern slavery risks

Policy commitment, policies and procedures

Medtronic strives to conduct its business in a manner that demonstrates our respect for internationally recognised human rights and the dignity of all people. Our Global Human Rights Framework, Global Human Rights and Labor Standards Policy, Global Anti-Human Trafficking and Forced Labor Policy, Code of Conduct and Global Supplier Code of Conduct outlines the foundation for Medtronic's standards and expectation for ethical and sustainable business conduct.

Our overall commitment and approach to human rights is embedded in our governing documents. The [Global Human Rights and Labor Standards Policy](#) and [Global Anti-human Trafficking and Forced Labor Policy](#) set forth Medtronic's commitment to respect internationally recognised human rights throughout its supply chain. The Human Rights and Labor Standards Policy statement guides the company's human rights work and includes principles on:

- Diversity and inclusion
- Fair Treatment
- Freedom from Forced Labour
- Free of child labour
- Fair compensation
- Freedom of Association

For more information on our policy commitment, see Medtronic's policies (hyperlinked above).

In addition, to support the implementation of Medtronic's commitments, Medtronic has numerous other global policies in place - including:

- Global Inclusion and Equal Employment Opportunity Policy
- Global Harassment and Other Forms of Offensive Behavior Policy
- Global Workplace Safety and Security Policy
- Global Environmental Health and Safety (EHS) Policy
- Voice Your Concern Policy

Medtronic is committed to ensuring that our supply chain reflects our values and beliefs by conducting business in ways that are consistent with Medtronic's applicable policies and practices, including adherence to principles of responsible sourcing of materials for our products. As part of our commitment to responsible sourcing and human welfare, Medtronic has set forth [Global Supplier Code of Conduct](#) and a Supplier Quality Excellence Manual that sets out general expectations related to promoting human rights and decent working conditions towards our suppliers. The Global Supplier Code of Conduct is available in 20 languages and can be found at Medtronic.com, '[Supplier Standards and Policies](#)'. Suppliers are also expected to comply with [Medtronic's Responsible Minerals Policy](#) which commits to compliance with the United States requirements known as the Dodd-Frank Act.

Governance structure

Medtronic has a company-wide global approach to human rights due diligence processes which is integrated into our governance structure. Our shared ownership structure reflects the horizontal nature of the company's human rights processes and the size and complexity of the organisation. At the time of reporting, the responsibility for Medtronic's due diligence activities is shared between Enterprise Risk Management, Human Resources, and Global Supply Management – with support from Trade Compliance and Legal.

The Human Resources department holds the responsibility for the Global Human Rights program related to internal facilities, and the Global Supply Management team oversees the company's Responsible Supplier Management Program. Medtronic's Enterprise Risk Management function, in partnership with Human Resources, has responsibility to ensure program consistency across the company's human rights due diligence activities.

Further details on how Medtronic's business is organised can be found in [Medtronic's Impact Report](#).

Medtronic's approach to human rights due diligence

(a) Due diligence related to internal facilities

Medtronic conducts annual risk assessments of our internal operations facilities, and assessments of our commercial facilities every third year. Facilities are assessed for human rights risks including child labour, fair treatment, forced labour, freedom of association, health and safety, and remuneration. The program has identified certain groups particularly vulnerable to human rights abuses, including children, foreign and domestic migrant workers, poorly educated, local communities, women, indigenous people, and ethnic minorities, which varies based on location. The assessment process is based on various factors such as the type of work performed at the internal facility, as well as the country specific risk factors related to the location of the facility, including country laws, enforcement of laws, and other factors. Based on the information gathered during the

assessment, the facility is given a risk score that provides the basis for monitoring and need for additional operational control to reduce or mitigate potential risk.

Medtronic annually publishes a public report detailing the human rights due diligence work related to internal facilities. As such, more information about the process, can be found in the [Global Human Rights Program Report](#). At this time of reporting, our due diligence activities conducted at our internal facilities during the reporting period have not uncovered any actual adverse effects on human rights or working conditions.

Moreover, Medtronic has an established approach related to ensuring the health and safety of people, promote diversity and inclusion, and prevent discrimination and harassment. These risks and impacts are routinely managed through our internal processes and procedures. Our disclosure on handling of these risks and other risks relevant to our internal workforce are covered separately and elaborated on in the [Medtronic's Impact Report](#).

(b) Human Rights Due diligence across our supply chain


Medtronic has adopted a risk-based approach to identify, assess and manage risk of adverse human rights impacts related to its supply chain activities. The due diligence process is integrated in the Responsible Supply Management Program, covering supplier selection and supplier performance management. It includes both a ‘*Supplier Sustainability Assessment Program*’ and a ‘*Conflict Minerals Program*’.

Supplier Sustainability Assessment Program

The Supplier Sustainability Assessment Program monitors suppliers’ compliance and performance against Medtronic’s standards, prioritising suppliers where Medtronic has the highest spend and those deemed to be highest risk.

Using self-assessment surveys and on-site audits, we determine supplier risk in four areas: labour and human rights, environment, ethics, and sustainable procurement.

Our risk determination dictates the frequency of a supplier’s self-assessment. Low-risk suppliers complete assessments every three years, while medium and high-risk suppliers complete assessments every two years and annually, respectively. We issue corrective action requests to all suppliers identified as medium or high-risk, and we expect them to promptly address high-priority incidents of non-compliance. We also conduct on-site workplace conditions inspections and audit the business practices of high-risk suppliers.



Responsible Minerals Program

Some of our products contain tin, tungsten, tantalum, or gold. In the Democratic Republic of Congo and neighbouring countries, mining and processing of

these metals has been linked to funding armed conflict. To promote the use of responsibly sourced minerals, we continue to:

- Support the U.S. Dodd-Frank Act, which requires companies to disclose the use of any such conflict minerals
- Require suppliers to comply with the law and uphold responsible sourcing practices
- Reference conflict minerals in supplier agreements and purchase orders

- Participate as a member of the Responsible Minerals Initiative (RMI)
- Follow the Organization for Economic Cooperation and Development (OECD) guidance on conflict minerals – including surveying suppliers to collect data on smelters in their supply chains.

More information on our approach is available in our Responsible Minerals Policy.

Training

To strengthen employees' risk awareness and ensure adequate competence to carry out due diligence activities, Medtronic provides Responsible Supply Management training for employees in our procurement, sourcing, and supplier quality groups. Employees with direct responsibilities for supplier selection and management are required to complete the Responsible Supply Management awareness training, with training completion metrics formally monitored. The training includes an overview of potential human rights and labour standards issues, the details of the Global Supplier Standards and supplier compliance requirements, and supplier selection and management best practices. Employees working in supply management are trained on awareness on issues that may cause adverse impacts on human rights and labour standards, such as how their decisions can potentially impact factory working conditions.

Medtronic also requires additional relevant training including:

- All new employees and most new contractors complete Code of Conduct training within their first 60 days. Annually, all employees and most contractors complete Code of Conduct training and certify their adherence to the principles of the Code of Conduct;
- Compliance training provided to each new agent or distributor within 6 months of appointment, and at least every two years thereafter.

Medtronic Australasia also extends the Responsible Supply Management training to Medtronic Australasia's local leadership team and additional relevant employees.

Reporting and grievance procedures

Medtronic has an anonymous, independently operated, hotline (*Voice Your Concern*) to support the Global Human Rights Framework, whereby Medtronic employees and suppliers, including other third parties, can report concerns and violations of Medtronic policies on human rights. In the event that a human rights complaint is received through this reporting line, the claim is investigated and substantiated through an internal analysis of the facility in question, including a re-evaluation of the overall facility risk score and implementation of additional operational controls (as required). The [Voice Your Concern](#) reporting line is available to all Medtronic employees, contract staff, suppliers, and the public. Medtronic has a global investigation team responsible for supporting internal processes around alleged misconduct.

Medtronic also maintains other global and local reporting and grievance procedures, such as:

- Medtronic Organisational Health Survey – This is a tool which provides all employees the opportunity to take part in an anonymous survey about how they feel about their employment, the work they do and the person they report to;
- Medtronic Whistleblowing Policy (ANZ) – This Policy applies to all Medtronic Australasia employees and provides specific provisions underpinned by current Australian legislation in relation to Qualifying Disclosures and how they are managed.

Assessing the effectiveness of actions taken to address modern slavery risks

Measures relevant to own facilities on human rights: internal risk assessments and monitoring of internal facilities

At the time of reporting, all 62 Medtronic manufacturing facilities were assessed in FY25. All assessed facilities, regardless of risk score, receive operational controls. Operational Controls may include new policy development, existing policy updates, training and awareness regarding human rights, and scheduling of an on-site audit. When needed, additional operational

controls are put in place based on identified risk from the internal assessments of internal facilities. An Overall Ranking of High will result in escalation to the Emergency Review Board and involves requests to rectify / mitigate the issue(s) within a given timeframe. Whereas an overall ranking of medium will require the development of a remediation plan specifying facility correction actions that is monitored and verified to ensure the issue is resolved on time. The operational controls that are put in place to reduce or mitigate risk are monitored to ensure their implementation and that they are having the desired positive impact.

For further information on the company's handling of potential risks of adverse impacts relating to our own facilities, see our [Global Human Rights Program Report](#).

Measures to identify and mitigate risk of adverse impacts in our supply chain

Medtronic strongly opposes substandard working conditions related to the company sourcing practices and has several processes and measures in place to ensure any potential risks of human rights violations are identified and mitigated. When any risk of adverse impacts linked to Medtronic's sourcing practices is discovered, the company acts to mitigate and rectify any findings proportionate to the severity and scale of the potential negative impact.

Supplier risk assessments, audits and requests for corrective action

As detailed above in this statement, Medtronic has a Human Rights framework in place that includes human rights due diligence and risk assessment processes across our supply chain. The Global Supply Management team conducts risk assessments and on-site audits where relevant. Where areas of risk and / or non-compliance are identified, corrective action requests are issued to suppliers identified as a medium or high-risk, and they are expected to promptly address high-priority incidents of non-compliance.

Sustainability risk score

Medtronic has partnered with EcoVadis to support supply chain risk assessments and to improve sustainability impacts, including human rights. In FY25 Medtronic assessed 446 suppliers on their sustainability performance.

Supplier audits

Medtronic works with a third party to conduct on-site audits of suppliers that receive a high-risk score from the supplier sustainability assessment. At this point of reporting, on-site audits of 6 suppliers and 5 follow-up audits have been conducted in FY25. The scope of these audits included labour, wages and working hours, health and safety, and business practices.

Strengthening efforts to identify and mitigate supply chain risks by integrating a Supplier Risk Mapping tool

Due to the limited transparency and traceability in global supply chain data, Medtronic recognises the potential risks associated with adverse impacts in our supply chain. In response, Medtronic is continuously developing and is improving its processes to identify the source of individual components and raw materials.

In FY25, we continued the use of the internally developed Supplier Risk Mapping Tool. This tool was piloted in FY22 to analyse tier 1 suppliers related to their geographic location and industry, also considering volume of procurement spend data. Medtronic is currently advancing the tool to increase transparency into the lower tiers to strengthen our supply chain risk assessments processes. To achieve desired objectives, we have partnered with Everstream Analytics, a leading supply chain mapping provider, to aggregate multiple data streams and enable mapping of tier 1 and sub-tier suppliers across our supply chain.

Risk mitigation related to conflict minerals

Medtronic has taken steps to mitigate risks in response to concerns regarding the supply chain of medical devices, particularly in relation to conflict minerals. Actions include increasing and requesting traceability throughout the supply chain, seeking contractual safeguards, engaging with industry initiatives and investigating opportunities for alternative sourcing routes.

The complexity of the company’s supply chain involves limited influence over the behaviour of these smelters and refiners with whom Medtronic does not have a direct business relationship. Moreover, because of the geographic diversity and ongoing changes in our supply chain, Medtronic often has significant difficulty identifying those suppliers who are further upstream from our direct suppliers. Despite this, Medtronic continues our efforts to promote the use of responsibly sourced minerals – including requesting suppliers to eliminate red-flag smelters from their supply chain.

Addressing the systemic challenges related to the industry's use of conflict minerals requires a collective effort from industry peers and partners. As such, Medtronic has become a member of the Responsible Mining Initiative (RMI), which allows the company to play a role in shaping industry policies, engage with stakeholder groups, and provides access to validated data on facilities related to conflict minerals.

For more details on the due diligence activities undertaken as part of the Conflict Minerals Program, refer to Medtronic’s Responsible Minerals policy and ‘Conflict Minerals Disclosures Report’ publicly available through the Company’s website: Medtronic.com (Under the “Our company” caption and “SEC filings” sub caption).


Regional Suppliers to Medtronic Australasia

(a) Direct procurement

Financial Year 2025 saw the rationalisation of our Regional Supplier base ramp up due to the closing of a local business, which relied heavily on Regional Suppliers. Whilst there were still purchases from these Regional Suppliers in the early part of the Financial Year, they are now fully closed which will result in a reduction in risk next Financial Year. These closures represent a 40% reduction in Regional Suppliers and more than half in Moderate Response Countries.

The details are set out in the table and graph below.

| Regional Supplier by grouped by source country’s Global Slavery Index 2023 rating of Government Response | | | | | |
|---|------|------|------|------|------|
| Grouping | FY21 | FY22 | FY23 | FY24 | FY25 |
| Very High Response | 15 | 14 | 15 | 15 | 15 |
| High Response | 3 | 4 | 3 | 3 | 2 |
| Moderate Response | 19 | 14 | 13 | 11 | 10 |
| Total | 37 | 32 | 31 | 29 | 27 |



Figures 4 and 5: Change in mix of direct Regional Supplier base (regional suppliers to Medtronic Australasia) grouped by source country’s Global Slavery Index 2023 rating.

To reduce the risk of modern slavery within our supply chain, we have implemented robust programs, including third party audits that can identify any instances of unethical labour practices. If these audits identify any risks, we will work closely with these suppliers to implement corrective measures, ensuring that they align with the stringent ethical standards set out in our Supplier Code of Conduct to prevent recurrence of such practices.

Our approach is grounded in the principle of continuous improvement, recognising that modern slavery risk management is an ongoing process. We will regularly review our strategies and processes, incorporating feedback from stakeholders, such as employees, suppliers, and third-party auditors. This allows us to identify areas for improvement and adapt our practices to better mitigate risks. This ensures that our supply chain remains vigilant against modern slavery.


(b) Indirect procurement

Facilities tenders and certain indirect procurement tenders have continued incorporating modern slavery expectations as conditions of awarding future contracts. In addition, we utilise our third-party partner to assess certain suppliers on the global level. The assessments include compliance with labour and human rights as an essential component. Each year, Medtronic globally will assess a number of suppliers including the ones which provide indirect goods/services to Australia, and Medtronic Responsible Supply Management team will prepare the global supplier sustainability risk scorecard accordingly. We have utilised the risk scorecard and considered Australian suppliers based on the overall risk rating, and we will also identify high risk suppliers, if any, and take actions including but not limited to on-site audits in future reporting periods, if deemed appropriate.

Further information

For any questions or concerns regarding Medtronic Australasia’s efforts regarding modern slavery risks, please email anzmedtronicenquiries@medtronic.com.

Signed:

DocuSigned by:

F94E212C1AE441F...

Liz Carnabuci

Vice President, Managing Director ANZ
Medtronic Australasia Pty Ltd